Mechanism:HER2xCD3 (bispecific mAb)
Primary Indication:HER2 positive cancers such as breast Cancer, gastric cancer & ovarian Cancer
GBR 1302, a HER2xCD3 bispecific antibody, is the first clinical candidate based on Glenmark’s proprietary best-in-class BEAT® platform. Preclinical study results from redirected lysis assays suggest GBR 1302 has superiority to current 1st and 2nd line HER2-targeted monoclonal antibodies through faster and more complete killing of HER2+ tumor cells. If confirmed in clinical trials, GBR 1302 will constitute an innovative treatment for HER2 positive cancers, and potentially prove superior to the currently available monoclonal antibody treatments. Glenmark has initiated a Phase 1 trial for GBR 1302 in Germany and will soon expand recruitment to the USA.